Objectives: This observational study was requested by French health authorities to determine the impact of lopinavir/ritonavir (Kaletra w ) on antiretroviral resistance in clinical practice. Virological failures of lopinavir/ritonavir and their effects on the resistance to protease inhibitors and reverse transcriptase inhibitors were evaluated in protease inhibitor-experienced patients.
Introduction
Lopinavir/ritonavir (Kaletra w , Abbott Laboratories, Abbott Park, IL, USA) is recommended for the treatment of adults and children with HIV-1 infection in association with other antiretrovirals. 1 Studies have reported the selection of HIV-1 strains resistant to lopinavir in the presence of increasing lopinavir concentrations alone and with ritonavir using in vitro passages. These passages revealed a sequential appearance of mutations in the protease gene I84V-L10F-M46I-T91S-V32I-I47V or selected I84V and I50V/M46I mutants. 2, 3 Clinical studies in first-line lopinavir/ ritonavir treatment have shown that the majority of viral isolates do not reveal major protease inhibitor (PI) resistance mutations and retained genotypic and phenotypic susceptibility to lopinavir/ritonavir. 4 However, in a few isolated cases selection of primary mutations occurred. 5, 6 One study showed a new pathway leading to lopinavir/ritonavir resistance with the selection of L76V and M46I mutations. 7, 8 In cases of HIV-1-infected patients who were pretreated with PIs, the virological response to lopinavir/ritonavir depended on virus resistance genotype and genotypic inhibitory quotient (GIQ). Several studies were conducted to determine a lopinavir/ ritonavir genotypic score of resistance. 9 -12 In the Agence Nationale de Recherches sur le SIDA (ANRS) algorithm, resistance to lopinavir/ritonavir is defined as the presence of mutations I47A 6, 13 or L76V 7, 8 or having at least six mutations among L10F/I/R/V, K20M/R, L24I, L33F, M46I/L, I50V, F53L, I54M/L/T/V, L63P, A71I/L/V/T, V82A/F/S/T, I84V and L90M, and possible resistance is defined as having four or five mutations among this list (last ANRS algorithm: http://www.hivfrenchresistance.org). A few studies have documented the patterns of mutations selected in patients treated with lopinavir/ritonavir who are highly experienced with antiretroviral therapy. 12, 14 The present study, named EOLE, was a post-registrational study requested by the French health authorities to determine the impact of lopinavir/ritonavir on antiretroviral resistance. The evaluation was limited to patients who were experienced with PIs, as the emergence of resistance to lopinavir/ritonavir after first-line therapy is considered rare. The virological failure of lopinavir/ritonavir and its effects on resistance to PIs and reverse transcriptase (RT) inhibitors were evaluated. In this work, we characterized the evolution of protease and RT resistance genotypes by describing the nature and frequency of mutations selected under lopinavir/ritonavir treatment, analysed their impact on cross-resistance to other PIs and studied the factors associated with the selection of mutations.
Patients and methods

Study population
EOLE was a multicentre cross-sectional study with data collection from patients with the following eligibility criteria: age ≥18 years and prior antiretroviral experience with at least one PI and virological failure while on lopinavir/ritonavir-containing antiretroviral therapy. Lopinavir/ritonavir was the only authorized PI in the antiretroviral therapy. Virological failure was defined as a plasma HIV-1 viral load (VL) .50 copies/mL after at least 3 months of treatment with a regimen containing lopinavir/ritonavir. For all patients, a resistance genotypic test was available both prior to baseline (with a mean of 8.9 months) and at failure. 
Ethics
The present study was carried out in accordance with the Declaration of Helsinki and was approved by the Comité de Protection des Personnes (CPP) of Pitié-Salpêtrière Hospital, Paris, France. All patients gave written informed consent to the collection of data.
HIV-1 RNA quantification
Quantification of plasma HIV-1 RNA was performed using the Amplicor Monitor assay (Cobas 1.5, Roche Diagnostics, Basel, Switzerland), which has a lower limit of detection of 50 copies/mL.
Genotypic resistance testing
For each virological failure identified, genotype results were collected both at failure and at baseline, before lopinavir/ritonavir initiation. When genotype results were not available, genotypes were determined from the frozen samples stored in the laboratory. The RT and protease gene sequences were determined using population sequencing according to the ANRS consensus method. 15 RT and protease mutations were described at baseline and at failure according to the IAS-USA list. 16 Resistance to PIs was measured according to three categories: resistance, possible resistance and susceptible. Resistance to lopinavir/ritonavir was defined as having at least six mutations among L10F/I/R/V, K20M/R, L24I, L33F, M46I/L, I50V, F53L, I54M/L/T/V, L63P, A71I/L/V/T, V82A/F/S/T, I84V and L90M, and possible resistance was defined as having four or five mutations according to the last ANRS resistance algorithm (http://www. hivfrenchresistance.org).
PI plasma concentration determinations
Blood samples of patients treated with a lopinavir/ritonavir-containing regimen (400/100 mg twice a day) were collected in EDTA tubes at months 3 -6. The interval between last drug intake and sampling was recorded by nurses. Lopinavir trough plasma concentrations were measured by ultra-performance liquid chromatography coupled with tandem mass spectrometry (Acquity UPLC w -Acquity TQD w , Waters Corporation, Milford, MA, USA) using a slightly modified method described previously 17 after sample extraction 12+2 h after the last drug intake. The lopinavir and ritonavir methods were validated over plasma concentration ranges of 20 -10000 and 20-5000 ng/mL, respectively, with lower limits of quantification of 5 and 5 ng/mL, respectively. The between-assay bias for lopinavir and ritonavir was below 9% and 10% for all assays, respectively. The GIQ, defined as the ratio between the trough plasma concentration of lopinavir and the number of lopinavir mutations, was determined as described previously.
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Statistical methods
Weighted analyses were used to derive representative estimates of the percentage of patients with acquisition of resistance mutations and of acquisition of resistance to a drug, with the weight based on the number of patients followed at each centre. The estimates of the number of patients followed in each centre were derived from the French Hospital Database on HIV (FHDH ANRS CO4) and from the Aquitaine ANRS CO3 Cohort. Descriptive statistics were used to summarize patient characteristics and to describe the evolution of VL and CD4 cell count between baseline [day 0 (D0)] and virological failure, time of treatment and formulation and dose of lopinavir/ritonavir. McNemar's test was used to evaluate the change in prevalence of each mutation between D0 and failure and the evolution of PI resistance according to the ANRS resistance algorithm. Results for tipranavir were interpreted only for patients with subtype B viruses (n¼52). The evolution of PI resistance between D0 and failure was also assessed using the genotypic susceptibility score (GSS) and compared using the Wilcoxon signed-rank test. The GSS was calculated according to the last ANRS AC-11 genotype interpretation algorithm (www.hivfrenchresistance.org): 0 or 1 if resistant or susceptible to the drugs of the current therapy, respectively. Logistic regression was used to search for predictive factors of occurrence of at least one new PI mutation or of some particular mutations because of frequency. Factors included in the univariate model were age, gender, antiretroviral treatment history, HIV-1 subtype, CD4 cell count and VL at D0 and the number of PI mutations at D0 according to the 2008 IAS list. In a second analysis, lopinavir/ritonavir trough plasma concentration (continuous dosage, in classes and GIQ) was also included a as predictive factor in the model. The variables with univariate P,0.20 were Lambert-Niclot et al.
included in the multivariate analysis. An automatic backward selection method with an output threshold of 0.05 was then carried out.
Results
Patient characteristics
Seventy-two patients were included. The main characteristics of the study population are reported in Table 1 . The mean viral load at baseline was 4 log 10 copies/mL (1.6-6.5). All patients had been exposed to antiretrovirals for .1 year, with some patients having up to 18 years of exposure. On average (+SD), the period of exposure was 9+4 years for antiretrovirals and 7+3 years for combined antiretrovirals. All patients had been exposed to at least one nucleoside reverse transcriptase inhibitor (NRTI) and at least one PI. Approximately 79% of patients had been exposed to at least four NRTIs and 61% to at least three PIs. More than 69% of patients had been exposed to a nonnucleoside reverse transcriptase inhibitor (NNRTI). Few patients had received enfuvirtide (4.7%) or an integrase inhibitor (3.1%) and none had received a chemokine receptor 5 (CCR5) antagonist. The reason for the switch to lopinavir/ritonavir therapy (400/100 mg twice a day) was virological failure in the majority of cases (69.1%). Patient decision, toxicity and lack of adherence were responsible for the switch in 7.8%, 6.7% and 6.5% of patients, respectively.
Patient characteristics at time of virological failure
All the patients were receiving antiretroviral therapy at the beginning of the study. The antiretrovirals co-prescribed with lopinavir/ ritonavir are listed in Table 1 . The antiretrovirals most often co-prescribed together with lopinavir/ritonavir were tenofovir, lamivudine, emtricitabine and abacavir. Lopinavir/ritonavir was used as a single-drug regimen in 4.2% of all patients.
The duration of treatment to viral rebound with lopinavir/ritonavir ranged from 2.5 to 87.6 months, with a median of 13.1 months. At the time of virological failure, the median (IQR) VL was 3.4 log 10 copies/mL (1.2), with a median decrease of 0.3 log 10 copies/mL (1.3) from D0. The median CD4 cell count was 339 cells/mm 3 (315) and increased by a median of 45 cells/mm 3 (168) from D0. The measurement of trough plasma concentrations of lopinavir was performed for 39 of 72 enrolled patients. The median lopinavir concentration was 4953 ng/mL (5763). The percentages of patients with a plasma concentration equal to or exceeding 1, 1000 and 3000 ng/mL were 93.3%, 89.6% and 78.0%, respectively. The median of the GIQ was 751.8 (972.8), which corresponded to IQR25% of the Early Access Program GIQ. 11 Our GIQ was low, although lopinavir C min s were adequate with the daily dose administered. In fact the low GIQ was due to a large number of lopinavir mutations.
Resistance analysis
Among the protease mutations from the 2008 IAS list, the mutations L10I, I13V, K20I, M36I, M46I, I54V, I62V, L63P, H69K, A71V, V77I, L90M and I93L were present in .20% of patients at D0 and failure. At failure, at least 50% of the viruses harboured a mutation in protease at positions 10, 20, 36, 63 and 71. In particular, the mutations M36I and L63P were found in .50% of the viruses at failure. Finally, in the protease, eight mutations were significantly selected between D0 and failure: L10V, K20R, L33F, M36I, I47V, I54V, A71V and I85V (P,0.05; Figure 1 ). Single mutation V77I was significantly less prevalent at failure versus D0 (P,0.05) among the 22 viruses harbouring this mutation at D0. There was no evolution of RT mutations between D0 and failure. Only mutations K70R and G190A were significantly less prevalent at failure versus D0 (P,0.05). Indeed, among 14 patients with viruses with K70R mutations and 9 patients with viruses with G190A mutations at D0, 4 and 3 patients, respectively, did not harbour the mutation at failure. 
Impact on PI resistance
This study was retrospective, so all genotypes prior to the initiation of lopinavir were not determined at the time of a previous failure and available to clinicians. At D0, 55.2% (n¼ 40) of viruses were classified as fully susceptible to lopinavir/ritonavir. For other PIs, the proportion of susceptible viruses ranged from 49% (n¼ 35) to 71% (n¼ 51), with the exception of darunavir and tipranavir, for which the proportions were considerably higher [93.2% (n¼ 67) and 97.7% (n¼ 51) of susceptible viruses, respectively]. The development of PI resistance is shown in Figure 2 . At failure, the proportion of resistant or possibly resistant viruses had increased from D0 for all PIs. In particular, the proportion of viruses susceptible to atazanavir, fosamprenavir and darunavir decreased significantly between D0 and failure (P,0.05). Among viruses susceptible to fosamprenavir at D0, 32% (n¼16) were resistant or possibly resistant at failure. This proportion was 26% (n¼ 14) for atazanavir and 16% (n¼ 7) for darunavir. The GSS for lopinavir/ritonavir averaged 0.5+0.5 at failure and declined on average by 0.1+0.4 from D0. For all PIs, GSS significantly decreased between D0 and failure except for darunavir and nelfinavir.
Among evaluable patients, 25 had an infection with a non-B HIV-1 subtype, with 9 of 25 patients presenting with a CRF02_AG subtype. There were no significant differences in the selection of mutations, evolution of GSS and proportions of resistant or possibly resistant viruses in non-B subtypes between D0 and failure.
Factors associated with the selection of at least one PI mutation A univariate logistic regression model was used to identify factors associated with the selection of at least one new PI mutation at baseline, which occurred in 14 patients (19%; Table 2 ). The number of PI mutations was significantly associated with an increased risk of occurrence of at least one PI mutation (P ¼ 0.046). On the other hand, female sex was associated with a decreased risk of the selection of at least one new PI mutation (P ¼ 0.049). The results of the multivariate analysis showed that only the increasing number of PI mutations at D0 according to the 2008 IAS list was independently associated with the emergence of at least one new PI mutation. Indeed, patients who had more than seven PI mutations at D0 showed a significantly higher occurrence of PI mutations compared with those who had fewer than four mutations (OR, 57.83; 95% CI, 1.97 -1694).
The occurrence of at least one new PI mutation between D0 and failure was also analysed in the patient population in which the plasma lopinavir concentration was measured (n¼39). In addition to the predictive factors studied previously, the lopinavir concentrations were included in the model. The pharmacological factors tested included lopinavir concentration as a continuous variable or in classes (,1 versus ≥1 ng/mL, ,1000 versus ≥1000 ng/mL and ,3000 versus ≥3000 ng/mL) and GIQ or its log as a continuous variable. The results of this analysis showed that lopinavir concentration or GIQ was not significantly associated with the occurrence of at least one PI mutation.
Discussion
This observational study described the development of PI resistance in a population of patients pretreated with antiretrovirals from different therapeutic classes, including PIs, and who failed while receiving lopinavir/ritonavir-based antiretroviral therapy. The analyses included all protease mutations rather than only PI mutations from the IAS list. Thus, mutations in the protease Impact of lopinavir/ritonavir on antiretroviral resistance 2491 JAC significantly selected between D0 and failure were identified as L10V, K20R, L33F, M36I, I47V, I54V, A71V and I85V. These mutations belong to the current ANRS lopinavir/ritonavir algorithm, with the exception of M36I, I47V and I85V. However, mutations M36I and I47V were part of the score derived from the analysis of the lopinavir/ritonavir expanded access. 18 The mutations M36I and M36V have also been noted to be selected in vitro in the presence of lopinavir, 19 and the M36I substitution (together with M36V and M36L) has been observed, in vivo, in rebound virus isolates from patients treated with lopinavir/ritonavir. 4, 20 In addition, the I47V mutation arose during cell culture selection experiments in viruses grown in the presence of lopinavir. 2 Increased use of lopinavir/ritonavir correlates with increased frequencies of the I47V mutation as an intermediate towards the acquisition of I47A. 14, 21 The mutation I47V was also selected under therapy with darunavir/ritonavir. 22, 23 Of note, the I85V mutation was not part of the resistance score of lopinavir/ ritonavir, but was associated with a reduced virological response to ritonavir-boosted atazanavir therapy in PI-experienced patients 24 and its selection may explain the increase in crossresistance to atazanavir. Thus, in the present study, the selection of mutations not belonging to the current lopinavir ANRS score, such as M36I, I47V and I85V, suggests that these mutations could themselves have an impact on lopinavir resistance. Further analysis is needed to clarify the role of these mutations as determinants of lopinavir resistance and to evaluate the impact of including them in lopinavir genotypic scores.
For darunavir, viruses in four patients evolved from susceptible to possibly resistant; this was linked to the selection of the I47V mutation in the current darunavir ANRS algorithm in three of the four patients. In the fourth patient, this was explained by the selection of I54V and I84V mutations.
For atazanavir, viruses in 14 patients evolved from susceptible to resistant; this was linked to the selection of mutations that are part of the atazanavir ANRS algorithm, particularly mutations at positions 10, 33, 46, 50, 84, 85 and 90.
For fosamprenavir, viruses in 16 patients evolved from susceptible to resistant; this was linked to the selection of mutations that are part of the fosamprenavir ANRS algorithm, particularly V32I and I47V for three of them or acquisition of one to seven mutations at positions 10, 33, 36, 54, 62, 82, 84 and 90.
The main predictive factor of the occurrence of mutations associated with resistance to PIs was the number of PI mutations already present at D0, with an increased risk for patients with more than seven IAS mutations, even if viruses were considered fully susceptible to lopinavir/ritonavir. This result suggests that lopinavir/ritonavir should be used as first-line treatment to avoid selection of PI resistance mutations in cases of virological failure. Finally, this study showed an increased percentage of patients with viruses resistant to fosamprenavir, atazanavir and darunavir at failure. Among patients with a virus susceptible to atazanavir at D0, 26% (n¼ 14) exhibited a virus resistant or possibly resistant at the time of failure. This proportion was 32% (n¼ 16) for fosamprenavir and 16% (n¼ 7) for darunavir. A high proportion (84%) of viruses remained susceptible to darunavir and 74% and 68% of viruses remained susceptible to atazanavir and fosamprenavir, respectively.
In this context, darunavir or tipranavir (the latter only for sub-type B) remains a viable treatment option in the event of virological failure of lopinavir/ritonavir. To compare and Lambert-Niclot et al.
determine the best treatment sequencing, similar studies should be performed for darunavir/ritonavir and atazanavir/ritonavir.
